Three-time-point PET analysis of 68Ga-FAPI-46 in a variety of cancers

• Verfasst von: Naeimi, Mahnoosh [VerfasserIn]
• Verfasst von: Choyke, Peter L. [VerfasserIn]
• Verfasst von: Dendl, Katharina [VerfasserIn]
• Verfasst von: Mori, Yuriko [VerfasserIn]
• Verfasst von: Staudinger, Fabian [VerfasserIn]
• Verfasst von: Watabe, Tadashi [VerfasserIn]
• Verfasst von: Körber, Stefan A. [VerfasserIn]
• Verfasst von: Röhrich, Manuel [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Kratochwil, Clemens [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Verfasst von: Giesel, Frederik L. [VerfasserIn]
• Titel: Three-time-point PET analysis of 68Ga-FAPI-46 in a variety of cancers
• Verf.angabe: Mahnoosh Naeimi, Peter L. Choyke, Katharina Dendl, Yuriko Mori, Fabian Staudinger, Tadashi Watabe, Stefan A. Koerber, Manuel Röhrich, Jürgen Debus, Clemens Kratochwil, Uwe Haberkorn, Frederik L. Giesel
• E-Jahr: 2023
• Jahr: April 1, 2023
• Umfang: 5 S.
• Fussnoten: Online veröffentlicht: 3. April 2023 ; Gesehen am 10.08.2023 ; Im Titel ist die Zahl 68 hochgestellt
• Titel Quelle: Enthalten in: Journal of nuclear medicine
• Ort Quelle: New York, NY : Soc., 1964
• Jahr Quelle: 2023
• Band/Heft Quelle: 64(2023), 4 vom: Apr., Seite 618-622
• ISSN Quelle: 2159-662X
• ISSN Quelle: 1535-5667
• DOI: doi:10.2967/jnumed.122.264941
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: 3-time-point
• Sach-SW: FAPI
• Sach-SW: fibroblast activation protein
• Sach-SW: PET
• Sach-SW: PET/CT
• K10plus-PPN: 1855113481

Abstract

A growing family of 68Ga-fibroblast activation protein inhibitor (FAPI) PET probes has shown promise in imaging a variety of medical conditions. 68Ga-FAPI-46, in particular, has emerged as unique for both its diagnostic and its theranostic applications; however, the optimal timing of PET remains unclear. Therefore, we evaluated uptake at 3 time points after 68Ga-FAPI-46 administration in a spectrum of tumor types. Methods: The cohort consisted of 43 patients with diverse cancer diagnoses undergoing 68Ga-FAPI-46 PET/CT at 3 time points (10 min, 1 h, and 3 h). We determined the tracer uptake based on SUVmean and SUVmax and on tumor-to-background-ratios (TBRs) (SUVmax/SUVmean). Results: There were 171 lesions in the 43 patients. Comparing all lesions at different time points, the mean SUVmax was maximal at 10 min (8.2) and declined slightly at 1 h (8.15) and 3 h (7.6) after tracer administration. Similarly, the mean SUVmax log still had a similar pattern in primary lesions at 10 min, 1 h, and 3 h (n = 30; 0.98, 1.01, and 0.98, respectively), lymph node metastases (n = 37; 0.82, 0.84, and 0.81, respectively), and distant metastases (n = 104; 0.81, 0.79, and 0.74, respectively). TBR also showed nonsignificant differences at the 3 times. Conclusion: 68Ga-FAPI-46 PET/CT imaging revealed remarkably stable tumor and background uptake as determined by SUV metrics and maintained high TBRs within 3 h of injection. Thus, it may be possible to scan with 68Ga-FAPI-46 within 10-20 min of injection, improving workflow and decreasing patient wait times. Confirmation of these findings in a larger cohort is under way.